Biomunex Pharmaceuticals

BIOMUNEX is a French biopharmaceutical company founded in Paris in 2014, focusing on the discovery and development of innovative bispecific antibody therapies based on its proprietary platform to address unmet medical needs. Leveraging its unique proprietary platform, BIOMUNEX is developing cutting-edge immunotherapies targeting various types of cancer. Its "plug-and-play" modular bispecific antibody BiXAb platform enables BIOMUNEX to develop candidates with high anti-tumor potential, superior manufacturability, and optimal drug properties. The BiXAb platform can also generate innovative bispecific antibodies in any other therapeutic area, such as immune-mediated inflammatory diseases, infectious diseases, or any other conditions where therapeutic bispecific antibodies could provide benefits.